1. Pink Sheet
  2. >>Market Access

Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year

 
• By Cathy Kelly

In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.

Boehringer Ingelheim May Face Price Negotiation For Six Drugs In 2026-2028. • Source: Shutterstock

Merck & Co., Inc.’s Keytruda and Bristol Myers Squibb Company’s Opdivo might be the only Medicare Part B drugs that will be subject to negotiated prices in 2028, the first year that Part B drugs will be eligible, according to an analysis by Sean Dickson, West Health Policy Center, and Immaculada Hernandez, University of California, San Diego.

Published in the Journal of Managed Care Pharmacy, the analysis forecasts the drugs and biologics whose prices will be negotiated by Medicare in the first three years of the program (see chart below), a tricky task that analysts have been focusing on since the law was enacted

Comment Deadline Approaching

The deadline to comment on the Medicare drug price negotiation guidance is 14 April

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.